From 1990 through 2013, the percentage of patients with non–small-cell lung cancer who never smoked rose from 8.0% to 14.9%.
In a 2004 Surgeon General report, the percentage of lung cancer patients who never smoked was estimated to be 10% to 15% of the total lung cancer population.
To reassess that figure, investigators performed a retrospective analysis of lung cancer registry data for the years 1990 to 2013 from three diverse sources: the University of Texas Southwestern Medical Center private patient facilities in Dallas, Parkland charitable county hospital in Dallas, and Vanderbilt University in Nashville. A total of 10,593 patients with non–small-cell lung cancer (NSCLC) and 1510 patients with small-cell lung cancer (SCLC) were evaluated.
Results were as follows:
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb